
ARKG Holdings of Exact Sciences Corp. (EXAS) - Updated Daily
Liquid BiopsyGenomicsGenetic Testing
Key Statistics
Statistics
⚖️Weighting | 🧢Market Cap |
---|---|
9.66% | $12.00b |
🏋🏿♂️Weight Rank In ARKG | 🌏Country |
1 | 🇺🇸United States |
🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
7 | $94.56 |
🎫ARK Ownership Percent | |
1.39% |
Description | |
---|---|
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com | |
Website | |
https://www.exactsciences.com/ |
Other ETFs That Hold EXAS
Research Notes and Commentary for EXAS
No Research Notes Found for EXAS